Japanese drugmaker Eisai has established asolid foothold in the U.S. market and found some success with its Merck & Co.-partnered oncology med Lenvima. And alongside BIogen, it's in the FDA queue for a landmark decision in Alzheimer's disease.

But Eisai'sstateside ambitions are broader than thatand as if to illustrate that point, the company is plotting a new U.S. headquarters on a high-tech New Jersey campus.

Eisai will relocateits U.S. headquarters from Woodcliff Lake, New Jersey, to a 15-story complex at the ON3 "bio-ecosystem" in Nutley, New Jersey, by the end of 2021,the Tokyo-based drugmaker said Tuesday.

Accelerate Clinical Operations Across Sponsors, CROs, and Partners

The most advanced life sciences organizations know that digital innovation and multi-platform integrations are essential for enabling product development. New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

Eisai will be the first biopharma tenant at the 116-acre site,formerly Roche'sU.S. headquarters, alongside residents from the healthcare, R&D and diagnostics fields. All told, Eisai will ship 1,200 of its corporate and R&D employees to the site, which the drugmaker called "technologically advanced and cutting edge."

The move will give Eisai the opportunity to collaborate outside biopharma to boost its oncology, Alzheimer's disease and neurological portfolios, the company said. The location in a brand-new hub will also help Eisai recruit talented employees, a spokesperson said.

Eisai's relocation comes as the Japanese drugmaker works to boost its top-sellingoncology med Lenvima, which has found a promising partnership with Merck's Keytrudaalong with its share of setbacks.

Meanwhile, the drugmaker is also working with partner Biogen on controversial Alzheimer's drug aducanumab, which the FDA accepted for priority review last week.The agency expects to decide the fate of the treatment by March 7.

RELATED:Merck, Eisai's Keytruda-Lenvima combo stonewalled in liver cancer after Roche's first-in-class green light

That was a big loss for the duo, which still has just one FDA approval to its credit inendometrial carcinoma.The partners hoped an approval would put themup againstRoches pairing of immuno-oncology agent Tecentriq and anti-VEGF drug Avastin, which recently scoredan FDA nod in first-line liver cancer with gold-standard data showing they could help patients live longer.

The two companies are stilltesting the Keytruda-Lenvima combo as a first-line liver cancer therapy in the phase 3 Leap-002 study, which isfully enrolled.

RELATED:Eisai preps for launch with insomnia med Dayvigo after buying out Purdue

Meanwhile, Eisai has worked to flesh out its neurology business, scoring an FDA approval in December for Dayvigo, an insomnia castoff from Purdue Pharma.

Eisai took full ownership of Dayvigoin May 2019 after itbought outPurdue's stake in the drug in 2015.The drug is an orexin receptor antagonist that works by targeting the wake center of the brain, according to EisaiCEO and president of itsglobal neurology businessIvan Cheung, who called the approval "very exciting" at the time.

See the original post:

Eisai will shift U.S. HQ to New Jersey 'bio-ecosystem' in move to boost oncology, neurology portfolios - FiercePharma